Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis

To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.

Inclusion Criteria: * Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis. * Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period. * Achieved PASI 75 response at the end of the induction period. * Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments. * Complete electronic medical record data available for extraction. Exclusion Criteria: * Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period. * Irregular maintenance treatment pattern, or substantial missing data. * Use of other targeted biologic agents or small molecule drugs during the maintenance period. * Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy. * Participation in other interventional clinical trials that may confound efficacy assessment.